Clinical Trials List
2022-02-01 - 2026-12-31
Phase III
Recruiting5
ICD-10D47.4
Osteomyelofibrosis
ICD-10D68.51
Activated protein C resistance
ICD-10D68.52
Prothrombin gene mutation
ICD-10D68.59
Other primary thrombophilia
ICD-10D68.61
Antiphospholipid syndrome
ICD-10D68.62
Lupus anticoagulant syndrome
ICD-10D68.69
Other thrombophilia
ICD-10D75.81
Myelofibrosis
ICD-10D75.89
Other specified diseases of blood and blood-forming organs
ICD-10D77
Other disorders of blood and blood-forming organs in diseases classified elsewhere
ICD-10D89.2
Hypergammaglobulinemia, unspecified
ICD-10E88.09
Other disorders of plasma-protein metabolism, not elsewhere classified
ICD-9289.8
Other specified diseases of blood and blood-forming organs
-
Trial Applicant
NOVARTIS (TAIWAN) CO., LTD.
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/02/01
Investigators and Locations
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Ching-Chan Lin 無
- 王秀慈 無
- Chi-Ching Chen 無
- Ming-Yu Lien 無
- 鄭富銘 無
- Che-Hung Lin 無
- Tzu-Ting Chen 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
18 participants
-
Global
400 participants
